Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Giving imatinib mesylate together with temozolomide may kill more tumor
cells.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate
when given together with temozolomide in treating patients with malignant glioma.
Status | Completed |
Enrollment | 65 |
Est. completion date | November 2008 |
Est. primary completion date | November 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed malignant glioma - Any of the following subtypes: - Glioblastoma multiforme - Gliosarcoma - Anaplastic astrocytoma - Anaplastic oligodendroglioma - Anaplastic oligoastrocytoma - Previous histologic diagnosis of a lower grade of glioma allowed if there is histologic evidence of progression to a diagnosis of malignant glioma - Multifocal disease allowed - Must have undergone prior conventional external-beam radiation therapy - Stable disease, disease recurrence, or relapsed disease - Must not have received any systemic therapy for this recurrence or relapse - No prior progressive disease - No central/systemic fluid collections (pericardial effusion, pulmonary effusion, ascites) = grade 2 - No evidence of intratumor hemorrhage on pretreatment diagnostic imaging, except for stable post-operative grade 1 hemorrhage PATIENT CHARACTERISTICS: - Karnofsky performance status 70-100% - Absolute neutrophil count > 1,500/mm³ - Hemoglobin > 9 g/dL - Platelet count > 100,000/mm³ - AST and ALT < 2.5 times upper limit of normal (ULN) - Bilirubin < 1.5 times ULN - Creatinine < 1.5 times ULN - No chronic renal disease - No active uncontrolled infection - No uncontrolled diabetes - No excessive risk of bleeding, as defined by occurrence of any of the following: - Stroke within the past 6 months - History of CNS or intraocular bleed - Septic endocarditis - No history of labile hypertension - No congestive heart failure - No poorly controlled hypertension - No myocardial infarction within the past 6 months - No history of poor compliance with antihypertensive regimen - No other severe and/or uncontrolled medical disease that would preclude study participation - No peripheral edema = grade 2 - No gastrointestinal bleeding - No gross hematuria - No other active systemic bleeding - Patients must not have experienced toxicity = grade 3 with prior treatment with either temozolomide or imatinib mesylate - No other primary malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix or other cancer not currently clinically significant nor requiring active interventions PRIOR CONCURRENT THERAPY: - See Disease Characteristics - Recovered from all prior therapy - Prior surgical resection(s) allowed - At least 2 weeks since prior surgery - At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas) - At least 2 weeks since prior external-beam radiotherapy - At least 2 weeks since prior investigational drugs - More than 1 week since prior biologic, immunotherapeutic, or cytostatic agents - No concurrent warfarin |
Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Duke Cancer Institute | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Cancer Institute (NCI) |
United States,
Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus te — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose | Yes | ||
Primary | Dose-limiting toxicity | Yes | ||
Primary | Safety and tolerability | Yes | ||
Primary | Pharmacokinetics | No | ||
Primary | Anti-tumor activity | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 |